Main Finding: A phase I trial supported the safety and feasibility of repeated intracranial infusions of B7-H3 CAR T cells for DIPG. Concept: B7-H3 is an immunoregulatory protein expressed on the ...
6Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback